Vector BioMed is a U.S.-based public benefit corporation and CDMO specializing in lentiviral vector design and manufacturing for cell and gene therapies. Launched following $15M in funding, the company provides essential lentiviral vector capabilities using their proprietary LENTIVERSE platform. They produce high-titer (>10^9 TU/mL) lentiviral vectors using a serum-free, chemically-defined process. Key differentiators include algorithm-optimized vector design, rapid turnaround (months from onboarding to GMP batch release), modular pre-validated systems to reduce costs and avoid royalty-based constraints, and a focus on making advanced therapies accessible in lower-resource settings. They partner with CIRM (California Institute for Regenerative Medicine) on lentiviral vector manufacture.
lentiviral vector design and manufacturing, LENTIVERSE platform, serum-free/chemically-defined process, algorithm-optimized vector design, high-titer viral vector production (>10^9 TU/mL), CAR-T vector manufacturing, cell and gene therapy CDMO
1 site worldwide
No reviews available yet.
No documents available.